Résumé
Checkpoint inhibitors could lead to a significant improvement in the management of bladder cancer. For metastatic bladder cancer, checkpoint inhibitors showed an improved overall survival and are currently recommended in second intention. Moreover, they could be used in replacement of standard chemotherapy in the case of muscle-invasive tumors. Finally, they appear to decrease the risk of recurrence after initial BCG treatment failure in the case of non-muscle-invasive tumors. For these three diseases forms, numerous ongoing trials are striving to demonstrate checkpoint inhibitors value.
Titre traduit de la contribution | TREATMENT OF BLADDER CANCER WITH IMMUNE CHECKPOINTS INHIBITORS |
---|---|
langue originale | Français |
Pages (de - à) | 391-395 |
Nombre de pages | 5 |
journal | Revue du Praticien |
Volume | 71 |
Numéro de publication | 4 |
état | Publié - 1 avr. 2021 |
Modification externe | Oui |